S
S. F. Paul Man
Researcher at University of British Columbia
Publications - 129
Citations - 9494
S. F. Paul Man is an academic researcher from University of British Columbia. The author has contributed to research in topics: COPD & Asthma. The author has an hindex of 46, co-authored 122 publications receiving 8779 citations. Previous affiliations of S. F. Paul Man include University of Alberta & St. Paul's Hospital.
Papers
More filters
Journal ArticleDOI
The role of female hormones on lung function in chronic lung diseases
TL;DR: Clinical and in-vivo data have demonstrated that females may be more susceptible to the pathogenesis of lung diseases, and the effect of female sex hormones in the context of these inflammatory airway diseases is reviewed.
Journal Article
Systemic inflammation in patients with COPD and pulmonary hypertension. Commentary
TL;DR: In this paper, the degree of systemic inflammation reflected by circulatory levels of C-reactive protein (CRP), tumor-necrosis factor (TNF)-a, and interleukin (IL)-6 in COPD patients with and without pulmonary hypertension was investigated.
Journal ArticleDOI
Rapid Mobilization of Intracellularly Stored RANTES in Response to Interferon-γ in Human Eosinophils
Paige Lacy,Salahaddin Mahmudi-Azer,Ben Bablitz,Stacey C. Hagen,Juan R. Velazquez,S. F. Paul Man,Redwan Moqbel +6 more
TL;DR: The findings suggest that RANTES may be mobilized and released by piecemeal degranulation upon stimulation, involving transport through a putative pool of small secretory vesicles.
Journal ArticleDOI
Changes in the bacterial microbiota in gut, blood, and lungs following acute LPS instillation into mice lungs.
Marc A. Sze,Masashi Tsuruta,Shun Wei Julia Yang,Yeni Oh,S. F. Paul Man,James C. Hogg,Don D. Sin +6 more
TL;DR: LPS instillation in lungs leads to acute changes in the bacterial microbiota in the blood and cecum, which can be modulated with antibiotics.
Journal ArticleDOI
Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD: a pilot study
TL;DR: Changes in serum SPD levels tracked well with changes in health status over a 3 month period in patients with severe COPD, suggesting that circulating SPD levels may be useful biomarkers to track health outcomes of COPD patients.